
### [NCIT:C7294](http://purl.obolibrary.org/obo/NCIT_C7294)
**Label:** Splenic Non-Hodgkin Lymphoma

**Subclasses:** [NCIT:C7308](http://purl.obolibrary.org/obo/NCIT_C7308) (Splenic Diffuse Large B-Cell Lymphoma), [NCIT:C7307](http://purl.obolibrary.org/obo/NCIT_C7307) (Splenic Follicular Lymphoma), [NCIT:C7309](http://purl.obolibrary.org/obo/NCIT_C7309) (Splenic Burkitt Lymphoma), [NCIT:C4663](http://purl.obolibrary.org/obo/NCIT_C4663) (Splenic Marginal Zone Lymphoma), [NCIT:C8459](http://purl.obolibrary.org/obo/NCIT_C8459) (Hepatosplenic T-Cell Lymphoma), [NCIT:C80309](http://purl.obolibrary.org/obo/NCIT_C80309) (Splenic Diffuse Red Pulp Small B-Cell Lymphoma), [NCIT:C5095](http://purl.obolibrary.org/obo/NCIT_C5095) (Recurrent Splenic Marginal Zone Lymphoma), [NCIT:C5096](http://purl.obolibrary.org/obo/NCIT_C5096) (Refractory Splenic Marginal Zone Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 52.77%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39899](http://purl.obolibrary.org/obo/NCIT_C39899) (Secondary Prostate Urothelial Carcinoma))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39897](http://purl.obolibrary.org/obo/NCIT_C39897) (Prostate Ductal Adenocarcinoma, Solid Pattern))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39896](http://purl.obolibrary.org/obo/NCIT_C39896) (Prostate Ductal Adenocarcinoma, Papillary Pattern))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39895](http://purl.obolibrary.org/obo/NCIT_C39895) (Prostate Ductal Adenocarcinoma, Cribriform Pattern))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3989](http://purl.obolibrary.org/obo/NCIT_C3989) (Parathyroid Hyperplasia))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39885](http://purl.obolibrary.org/obo/NCIT_C39885) (Acinar Prostate Adenocarcinoma, Lymphoepithelioma-Like Variant))) 39.52%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39880](http://purl.obolibrary.org/obo/NCIT_C39880) (Acinar Prostate Adenocarcinoma, Atrophic Variant))) 39.52%


